(Q84036431)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19513729%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

review article

1 reference

title

[Novel B-cell directed strategies for the treatment of rheumatic diseases] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19513729%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

I H Tarner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19513729%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

publication date

1 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19513729%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

number of pages

10

1 reference

Zeitschrift fuer Rheumatologie

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19513729%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19513729%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19513729%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

380-389

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19513729%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00393-009-0438-2

30 January 2020

exact match

0 references

cites work

A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors

1 reference

12 December 2020

Reduction in circulating dsDNA antibody titer after administration of LJP 394.

1 reference

12 December 2020

Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again

1 reference

12 December 2020

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study

1 reference

12 December 2020

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

1 reference

12 December 2020

Chemokines and their receptors in rheumatoid arthritis: future targets?

1 reference

12 December 2020

Expression profiling of metalloproteinases and tissue inhibitors of metalloproteinases in normal and degenerate human achilles tendon.

1 reference

12 December 2020

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls

1 reference

12 December 2020

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study

1 reference

12 December 2020

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

1 reference

12 December 2020

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

B-cell-directed therapies in systemic lupus erythematosus

1 reference

12 December 2020

Targeting CD22 as a strategy for treating systemic autoimmune diseases

1 reference

12 December 2020

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

1 reference

12 December 2020

Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies

1 reference

12 December 2020

Complement activation plays a key role in the side-effects of rituximab treatment

1 reference

12 December 2020

CD20 blockers eye crowded rheumatology market

1 reference

12 December 2020

Treatment of systemic lupus erythematosus with LJP 394.

1 reference

12 December 2020

Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma

1 reference

12 December 2020

The role of CD22 and other inhibitory co-receptors in B-cell activation

1 reference

12 December 2020

Epratuzumab in the therapy of oncological and immunological diseases

1 reference

12 December 2020

Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus

1 reference

12 December 2020

Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients

1 reference

12 December 2020

Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab

1 reference

12 December 2020

CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction

1 reference

12 December 2020

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

1 reference

12 December 2020

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

1 reference

12 December 2020

Treating patients with lupus with B-cell depletion

1 reference

12 December 2020

New approaches of B-cell-directed therapy: beyond rituximab

1 reference

12 December 2020

Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis

1 reference

12 December 2020

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.

1 reference

12 December 2020

CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice.

1 reference

12 December 2020

Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab

1 reference

12 December 2020

Association of hospital and surgeon procedure volume with patient-centered outcomes of total knee replacement in a population-based cohort of patients age 65 years and older

1 reference

12 December 2020

Block and tackle: CTLA4Ig takes on lupus

1 reference

12 December 2020

Associations between pain, function, and radiographic features in osteoarthritis of the knee

1 reference

12 December 2020

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

1 reference

12 December 2020

Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties

1 reference

12 December 2020

BAFF-targeting therapy, a promising strategy for treating autoimmune diseases

1 reference

12 December 2020

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

1 reference

12 December 2020

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo

1 reference

12 December 2020

B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies

1 reference

12 December 2020

10.1007/S00393-009-0438-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19513729%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference